Systemic Hepatic-Damage Index for Predicting the Prognosis of Hepatocellular Carcinoma after Curative Resection

Xing-hui Gao1 †, Shuang-shuang Zhang2 †, Hao Chen3, Yu-Hui Wang1, Chun-Hui Yuan1 and Fu-Bing Wang1 *

1 Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China, 2 Department of Dermatology, Shanghai Dermatology Hospital, Tongji University, Shanghai, China, 3 Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China

Purpose: We have developed a systemic hepatic-damage index (SHI) based on serum total cholesterol (TC) and high density lipoprotein levels (HDL) and determined its prognostic significance in hepatocellular carcinoma (HCC) patients undergoing resection.

Experimental Design: The SHI was analyzed in the training cohort of 188 HCC patients and in the validation cohort of 177 HCC patients. The systemic immune-inflammation index (SII) scores in the validation cohorts were also measured. Area under the receiver operating characteristic curve (AUC) was used to explore the prediction accuracy in HCC patients.

Results: An optimal cutoff point for the SHI of 2.84 stratified the HCC patients into high SHI (>2.84) and low SHI (≤2.84) groups in the training cohort. Univariate and multivariate analyses revealed the SHI was an independent predictor for overall survival and relapse-free survival, and prognostic for patients with negative α-fetoprotein and Barcelona Clinic Liver Cancer stage 0+A. The AUCs of the SHI for survival and recurrence were higher than other conventional clinical indices. Low SHI significantly correlated with vascular invasion. The SII scores were significantly higher in patients with low SHI compared with those with high SHI. HCC patients in SHI ≤ 2.84 group had shorter recurrence time and lower survival rate than HCC patients in SHI > 2.84 group.

Conclusions: The SHI was a potential biomarker for assessing HCC prognosis, and improving SHI level in HCC patients may be a promising therapeutic strategy decision. The poor outcome in HCC patients with low SHI scores might increase SII scores, increasing the possibility of recurrence and metastasis.

Keywords: system hepatic-damage index, hepatocellular carcinoma, recurrence, prognosis, survival

Abbreviations: HCC, Hepatocellular carcinoma; TTR, time to recurrence; OS, Overall survival; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; SHI, systemic hepatic-damage index; SII, systemic immune-inflammation index.
INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common malignancy with an increasing mortality rate worldwide. So far, surgical resection remains the most effective treatment for HCC patients; however, the prognosis of HCC patients who underwent curative resection remains unsatisfactory because of high recurrence possibility and metastasis incidence (Ji et al., 2009; Forner et al., 2012; Torre et al., 2015). The utility of conventional clinicopathological parameters, including histopathological characteristics, is insufficient for identifying patient subpopulations at high risk of tumor recurrence and metastasis. Therefore, it is urgent to develop new biomarkers for identifying tumor recurrence and metastasis so that post-operative rational adjuvant treatments can be provided timely.

The reasons for the high recurrence/metastasis rate in HCC are complex and multifactorial (Forner and Raoul, 2011). Hepatic damage is an important cause of recurrence and metastasis in HCC. In addition to tumor cells, immune and inflammatory cells such as neutrophils, platelets, and lymphocytes also contribute to tumor cell invasion into the peripheral blood, where tumor cells can survive and reseed distant organs (Chaffer and Weinberg, 2011; Hanahan and Weinberg, 2011; Casadei et al., 2016).

HBV infection leads to liver damage, relating to changes of the lipid metabolism. Several studies have shown that lower serum total cholesterol (TC) level correlated with cancer recurrence in HCC patients with hepatic resection, revealing the possibility to predict surgical outcome by preoperative clinical physiological parameters. Poorer surgical outcome in HCC patients with lower preoperative serum TC level might be caused by long-term liver dysfunction and malnutrition, implying the potential role of lipid composition in determination of operative outcomes in HCC patients (Irshad et al., 2007; Wang et al., 2016; Lee et al., 2016; Zhang et al., 2017). Recent studies have reported that serum high-density lipoprotein (HDL) is in relation to incident cancers especially breast cancer. These findings imply that HDL might play a major role in tumorigenesis and tumor progression (Lim et al., 2007; Li et al., 2016; Wang et al., 2016). However, an integrated indicator based on serum TC and HDL levels, which might be superior to reflect the correlation between hepatic damage and tumor stages, has not yet been reported in HCC. Moreover, the potential effects of serum TC and HDL levels on HCC recurrence and metastasis have not been elaborated.

In this study, an index based on serum TC and HDL levels, designated as the systemic hepatic-damage index (SHI), has been developed. The prognostic value of the SHI in HCC patients who underwent surgery was evaluated in two independent cohorts. The correlation between the SHI and systemic immune-inflammation index (SII) scores was also explored. We found that the SHI was a potential biomarker for predicting prognosis of HCC patients undergoing resection and that high recurrence rate in patients with low SHI score might be due to increased SII scores from the host.

MATERIALS AND METHODS

Study Design

Ethical approval for the use of human subjects was obtained from the Research Ethics Committee of Zhongnan Hospital. From January 2011 to June 2013, we recruited 188 HBV-HCC patients undergoing resection at Zhongnan Hospital as a training cohort. We next recruited a validation cohort of 177 HBV-HCC patients who underwent resection from July 2013 to December 2015 (Table 1). HCC was defined according to the data of imaging scans and biochemical assays, and diagnosis was confirmed by histopathology according to the criteria of the American Association for the Study of Liver Diseases guidelines. The stage of HCC was determined according to the BCLC guidelines (Bruix and Sherman, 2011). Tumor size was defined using the diameter of the single largest lesion. Tumor differentiation was defined using the Edmondson grading system (Wittekind, 2006).

Follow-Up and Tumor Recurrence

Follow-up for HCC patients ended in July 2016. The time to recurrence (TTR) was defined as the interval between surgery and any diagnosed intrahepatic or extrahepatic recurrence. The overall survival (OS) was defined as the interval between the date of surgery and the date of death, or the interval between surgery and the last observation.

Systemic Hepatic-Damage Index

The serum TC and HDL concentrations were determined by immunoassay, using Olympus AU5831 automated biochemistry analyzer. Serum samples were collected 2 days before surgery, and stored at −80°C before detection. The SHI was defined as follows: \( SHI = TC \times HDL \). The cutoff value of SHI for predicting tumor recurrence in the training cohort was determined by the X-tile 3.6.1 software (Camp et al., 2004). Results from X-Tile analysis revealed an optimal cutoff point for the SHI 2.84 in the training cohort (Supplementary Figure 1). Thus, patients were stratified into SHI high (>2.84) or low (≤2.84) groups for all subsequent analyses.

Systemic Immune-Inflammation Index

The SII was defined as follows: \( SII = P \times N/L \), where \( P, N \), and \( L \) were the preoperative peripheral platelet, neutrophil, and lymphocyte counts, respectively (Hu et al., 2014).

Statistical Analysis

Statistical analyses were performed using SPSS 16.0 software. Experimental values for continuous variables were expressed as the mean ± standard error of the mean. The chi-squared test, Fisher's exact probability tests and the Student's t-test were used to evaluate the significance of differences in data between groups. If variances within groups were not homogeneous, the non-parametric Mann–Whitney test or the Wilcoxon signed-rank test was used. Kaplan–Meier survival curves and log-rank tests was used to analyze the relationships between serum SHI scores and TTR and OS, and \( p < 0.05 \) was considered statistically significant.
TABLE 1 | The clinicopathologic characteristics of patients in the training and validation cohorts.

| Characteristics          | Training cohort | Validation cohort | P   |
|--------------------------|-----------------|-------------------|-----|
|                          | N = 188 (%)     | N = 177 (%)       |     |
| Age (years)              |                 |                   |     |
| ≤50                      | 69 (36.70)      | 68 (38.42)        | 0.747 |
| >50                      | 119 (63.30)     | 109 (61.58)       |     |
| Sex                      |                 |                   |     |
| Women                    | 26 (13.83)      | 32 (18.08)        | 0.316 |
| Men                      | 162 (86.17)     | 145 (81.92)       |     |
| HBsAg                    |                 |                   |     |
| Negative                 | 22 (11.70)      | 21 (11.86)        | 1.000 |
| Positive                 | 166 (88.30)     | 156 (88.14)       |     |
| Liver cirrhosis          |                 |                   |     |
| No                       | 40 (21.28)      | 43 (24.29)        | 0.533 |
| Yes                      | 148 (78.72)     | 134 (75.71)       |     |
| No. of tumors            |                 |                   |     |
| Single                   | 151 (80.32)     | 148 (83.62)       | 0.497 |
| Multiple                 | 37 (19.68)      | 29 (16.38)        |     |
| Tumor size, cm           |                 |                   |     |
| ≤5                       | 119 (63.30)     | 107 (60.45)       | 0.591 |
| >5                       | 69 (36.70)      | 70 (39.55)        |     |
| Tumor encapsulation      |                 |                   |     |
| Complete                 | 114 (60.64)     | 121 (68.36)       | 0.128 |
| None                     | 74 (39.36)      | 56 (31.64)        |     |
| Satellite lesion         |                 |                   |     |
| No                       | 165 (87.77)     | 161 (90.96)       | 0.397 |
| Yes                      | 23 (12.23)      | 18 (10.04)        |     |
| Vascular invasion        |                 |                   |     |
| No                       | 118 (62.77)     | 104 (58.76)       | 0.454 |
| Yes                      | 70 (37.23)      | 73 (41.24)        |     |
| Tumor differentiation    |                 |                   |     |
| I–II                     | 116 (61.70)     | 114 (64.41)       | 0.664 |
| III–IV                   | 72 (38.30)      | 62 (35.59)        |     |
| Child-Pugh score         |                 |                   |     |
| A                        | 177 (94.55)     | 159 (90.87)       | 0.175 |
| B                        | 11 (5.45)       | 9 (5.13)          |     |
| BCLC stage               |                 |                   |     |
| 0+A                      | 137 (72.97)     | 139 (78.53)       | 0.224 |
| B+C                      | 51 (27.03)      | 38 (21.47)        |     |
| AFP, ng/mL               | 2,391 ± 588     | 3,328 ± 858       | 0.360 |
| ALT, U/L                 | 39.27 ± 20.8    | 38.86 ± 20.1      | 0.415 |
| TB, umol/L               | 12.40 ± 0.40    | 11.80 ± 0.36      | 0.270 |
| Albumin, g/L             | 40.24 ± 0.53    | 40.40 ± 0.26      | 0.650 |
| PT, s                    | 12.38 ± 0.07    | 12.46 ± 0.08      | 0.458 |
| TC, mmol/L               | 1.10 ± 0.06     | 4.19 ± 0.07       | 0.317 |
| HDL, mmol/L              | 1.25 ± 0.02     | 1.27 ± 0.03       | 0.718 |
| SHI                      | 5.23 ± 0.14     | 5.35 ± 0.16       | 0.560 |

AFP, α-fetoprotein; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer; TB, total bilirubin; PT, prothrombin time; TC, total cholesterol; HDL, high-density lipoprotein; SHI, systemic hepatic-damage index.

RESULTS

Patient Characteristics

The clinicopathologic characteristics of HBV-HCC patients are shown in Table 1. In the training cohort, 89 of 188 HBV-HCC patients undergoing resection suffered recurrence with a median follow-up time of 30.9 months (range 0.3–36.8 months) and 51 of 188 HBV-HCC patients died before the last follow-up (median follow-up 33.0 months, range 3.2–36.8 months). The validation cohort comprised 61 of 177 HBV-HCC patients who confirmed recurrence with a median follow-up time of 20.0 months (range 1.0–30.3 months), and 140 HBV-HCC patients were still alive at a median follow-up of 22.5 months (range 4.0–30.3 months). In the training and validation cohorts, all clinicopathologic characteristics were similar (Table 1).

Prognostic Value of SHI in the Training Cohort

Using the X-tile 3.6.1 software, the optimal cutoff value (2.84) was set as to stratify HBV-HCC patients into low SHI (≤2.84) and high (>2.84) groups (Supplementary Figure 1). Kaplan-Meier analysis showed that TTR of HBV-HCC patients with low SHI was significantly shorter (p < 0.001, Figure 1A) and had higher recurrence rates than those with a high SHI (78.95 vs. 43.79%). Furthermore, the OS of HBV-HCC patients with low SHI was significantly shorter (p = 0.047, Figure 1A) than those with high SHI (42.11 vs. 25.44%). In multivariate analysis, the SHI was an independent indicator for TTR [Hazard ratio (HR), 2.97; 95% confidence interval (CI): 1.58–5.58; p = 0.001; Table 2] and OS (HR, 2.82; 95% CI: 1.25–6.39; p = 0.013; Table 2) of HBV-HCC patients. The area under curve (AUC) was used to assess the
Gao et al. SHI in the HCC

FIGURE 1 | Prognostic significance of SHI in HCC patients underwent curative resection. Prognostic significance of SHI in HCC patients undergoing resection. The Kaplan-Meier analysis of OS and TTR for SHI in the training (A) and validation (B) cohorts. Predictive ability of SHI was compared with other clinical parameters by ROC curves in the training (C) and validation (D) cohorts.

TABLE 2 | Multivariate Cox regression analyses in the training and validation cohort.

| Variables                        | TTR      |          |          |          | OS       |          |          |          |
|----------------------------------|----------|----------|----------|----------|----------|----------|----------|----------|
|                                  | HR (95% CI) | P       | HR (95% CI) | P       |          |          |          |          |
| TRAINING COHORT                  |          |          |          |          |          |          |          |          |
| AFP, ng/ml (>400 vs. ≤400)       | 0.832 (0.488–1.416) | 0.497 | 0.390 (0.171–0.892) | 0.026 |          |          |          |          |
| No. of tumors, (multiple vs. single) | 0.769 (0.414–1.425) | 0.403 | 0.979 (0.434–2.205) | 0.968 |          |          |          |          |
| Tumor size, cm (>5 vs. ≤5)       | 0.781 (0.466–1.326) | 0.361 | 1.115 (0.564–2.204) | 0.754 |          |          |          |          |
| Tumor encapsulation, (none vs. complete) | 1.000 (0.588–1.404) | 0.623 | 1.089 (0.597–2.194) | 0.781 |          |          |          |          |
| Satellite lesion, (yes vs. no)   | 1.167 (0.589–2.395) | 0.673 | 1.754 (0.692–4.444) | 0.236 |          |          |          |          |
| Vascular invasion, (yes vs. no)  | 0.987 (0.598–1.631) | 0.961 | 0.864 (0.448–1.665) | 0.662 |          |          |          |          |
| Tumor differentiation, (III-IV vs. I-II) | 1.072 (0.673–1.706) | 0.771 | 1.416 (0.770–2.605) | 0.264 |          |          |          |          |
| Child-Pugh score, (A vs. B)      | 1.777 (0.783–4.033) | 0.169 | 2.248 (0.848–5.961) | 0.103 |          |          |          |          |
| BCLC stage, (0+A vs. B+C)        | 0.593 (0.323–1.090) | 0.092 | 0.354 (0.147–0.853) | 0.021 |          |          |          |          |
| SHI (>2.84 vs. ≤2.84)            | 2.969 (1.579–5.581) | 0.001 | 2.824 (1.248–6.388) | 0.013 |          |          |          |          |

| VARIABLES                        |          |          |          |          |          |          |          |          |
|----------------------------------|----------|----------|----------|----------|----------|----------|----------|----------|
|                                  | HR (95% CI) | P       | HR (95% CI) | P       |          |          |          |          |
| VALIDATION COHORT                |          |          |          |          |          |          |          |          |
| AFP, ng/ml (>400 vs. ≤400)       | 1.610 (0.918–2.831) | 0.098 | 1.429 (0.683–2.989) | 0.343 |          |          |          |          |
| No. of tumors, (multiple vs. single) | 0.883 (0.415–1.875) | 0.745 | 0.820 (0.306–2.186) | 0.692 |          |          |          |          |
| Tumor size, cm (>5 vs. ≤5)       | 0.951 (0.473–1.915) | 0.889 | 0.873 (0.354–2.154) | 0.788 |          |          |          |          |
| Tumor encapsulation, (none vs. complete) | 0.650 (0.373–1.132) | 0.128 | 2.264 (1.087–4.718) | 0.029 |          |          |          |          |
| Satellite lesion, (yes vs. no)   | 1.244 (0.551–2.828) | 0.599 | 1.348 (0.478–3.802) | 0.572 |          |          |          |          |
| Vascular invasion, (yes vs. no)  | 0.800 (0.434–1.475) | 0.475 | 0.469 (0.206–1.069) | 0.072 |          |          |          |          |
| Tumor differentiation, (III-IV vs. I-II) | 1.051 (0.605–1.825) | 0.860 | 0.812 (0.388–1.698) | 0.579 |          |          |          |          |
| Child-Pugh score, (A vs. B)      | 2.691 (0.551–2.828) | 0.033 | 3.831 (1.164–12.602) | 0.027 |          |          |          |          |
| BCLC stage, (0+A vs. B+C)        | 1.459 (0.434–1.475) | 0.356 | 2.268 (0.793–6.490) | 0.127 |          |          |          |          |
| SHI (>2.84 vs. ≤2.84)            | 3.982 (1.506–8.783) | 0.001 | 4.417 (1.690–11.542) | 0.002 |          |          |          |          |

TTR, Time to recurrence; OS, Overall survival; HR, hazard ratio; CI, confidence interval; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; SHI, systemic hepatic-damage index. Bold value represents significant (P < 0.05).
TABLE 3 | Correlation between the SHI and clinicopathologic characteristics.

| Clinical characteristics | Training cohort | Validation cohort |
|--------------------------|----------------|------------------|
|                          | SHI ≤ 2.84 (N = 19) | SHI > 2.84 (N = 169) | P | SHI ≤ 2.84 (N = 13) | SHI > 2.84 (N = 164) | P |
| Age                      |                |                  |   |                |                  |   |
| ≤50                      | 7              | 62               | 1.000 | 7              | 61               | 0.250 |
| >50                      | 12             | 107              |       | 6              | 103              |       |
| Sex                      |                |                  |   |                |                  |   |
| Female                   | 4              | 22               | 0.307a | 1              | 31               | 0.468a |
| Male                     | 15             | 147              |       | 12             | 133              |       |
| AFP, ng/mL               |                |                  |   |                |                  |   |
| ≤400                     | 11             | 128              | 0.104 | 7              | 123              | 0.110 |
| >400                     | 8              | 41               |       | 6              | 41               |       |
| ALT, U/L                 |                |                  |   |                |                  |   |
| ≤75                      | 19             | 158              | 0.607a | 9              | 90               | 0.392a |
| >75                      | 0              | 11               |       | 4              | 74               |       |
| HBsAg                    |                |                  |   |                |                  |   |
| Negative                 | 1              | 21               | 0.704a | 0              | 21               | 0.370a |
| Positive                 | 18             | 148              |       | 13             | 143              |       |
| Liver cirrhosis          |                |                  |   |                |                  |   |
| No                        | 5              | 35               | 0.561 | 2              | 31               | 0.737a |
| Yes                      | 14             | 134              |       | 11             | 123              |       |
| No. of tumor             |                |                  |   |                |                  |   |
| Single                   | 18             | 133              | 0.130a | 10             | 138              | 0.450a |
| Multiple                 | 1              | 36               |       | 3              | 26               |       |
| Tumor size, cm           |                |                  |   |                |                  |   |
| ≤5                       | 9              | 110              | 0.139 | 5              | 101              | 0.378 |
| >5                       | 10             | 59               |       | 7              | 63               |       |
| Tumor encapsulation      |                |                  |   |                |                  |   |
| Complete                 | 9              | 105              | 0.225 | 11             | 110              | 0.232a |
| None                     | 10             | 64               |       | 2              | 54               |       |
| Satellite lesion         |                |                  |   |                |                  |   |
| No                       | 17             | 148              | 1.000a | 12             | 149              | 1.000a |
| Yes                      | 2              | 21               |       | 15             |        |       |
| Vascular invasion        |                |                  |   |                |                  |   |
| No                       | 10             | 108              | 0.453 | 4              | 100              | 0.042a |
| Yes                      | 9              | 61               |       | 9              | 64               |       |
| Tumor differentiation    |                |                  |   |                |                  |   |
| I–II                     | 11             | 107              | 0.805 | 7              | 107              | 0.548 |
| III–IV                   | 8              | 61               |       | 6              | 57               |       |
| Child-Pugh score         |                |                  |   |                |                  |   |
| A                        | 16             | 16               | 0.086a | 11             | 148              | 0.625a |
| B                        | 8              | 8                |       | 2              | 16               |       |
| B+C                      | 3              | 48               |       | 5              | 33               |       |
| BCLC stage               |                |                  |   |                |                  |   |
| O+A                      | 12             | 121              | 0.289a | 8              | 131              | 0.156 |
| B+C                      | 3              | 48               |       | 5              | 33               |       |

AFP: α-fetoprotein; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer; SLI, systemic hepatic-damage index. 

*Fisher exact test. Bold value represents significant (P < 0.05).

The discrimination ability of SHI and clinical factors for TTR and OS (Figure 1B). The AUC for SHI was 0.56 (95% CI, 0.48–0.65; Sensitivity, 0.169; Specificity, 0.959; Youden’s index, 0.128) for TTR, and 0.54 (95% CI, 0.44–0.663; Sensitivity, 0.157; Specificity, 0.919; Youden’s index, 0.112) for OS (Supplementary Table 1), which was the strongest factor among clinical factors (tumor size, tumor number, tumor differentiation, tumor encapsulation, vascular invasion, α-fetoprotein (AFP), and Barcelona Clinic Liver Cancer (BCLC) stage) for predicting tumor recurrence and survival of HBV-HCC patients.

**Correlation between SHI and Clinical Characteristics**

In the training cohort, the discrimination ability of SHI and clinical factors for TTR and OS (Figure 1B). The AUC for SHI was 0.56 (95% CI, 0.48–0.65; Sensitivity, 0.169; Specificity, 0.959; Youden’s index, 0.128) for TTR, and 0.54 (95% CI, 0.44–0.663; Sensitivity, 0.157; Specificity, 0.919; Youden’s index, 0.112) for OS (Supplementary Table 1), which was the strongest factor among clinical factors (tumor size, tumor number, tumor differentiation, tumor encapsulation, vascular invasion, α-fetoprotein (AFP), and Barcelona Clinic Liver Cancer (BCLC) stage) for predicting tumor recurrence and survival of HBV-HCC patients.

**Prognostic Value of SHI in the Validation Cohort**

The prognostic value of serum SHI level was further assessed using another independent cohort of 177 HBV-HCC patients. The results were similar to those of the training cohort (Figure 1). HBV-HCC patients with low SHI level have shorter TTR (p < 0.001, Figure 1B) and OS (p = 0.013, Figure 1B). Cox regression analyses showed that the serum SHI level was an independent indicator of TTR (HR, 3.98; 95% CI, 1.81–8.78; p = 0.001; Table 2) and OS (HR, 4.42; 95% CI, 1.69–11.54; p = 0.002; Table 2) of HBV-HCC patients. The discrimination ability of SHI was 0.54 (95% CI, 0.45–0.64; Sensitivity, 0.131; Specificity, 0.957; Youden’s index, 0.088) and 0.56 (95% CI, 0.45–0.67; Sensitivity, 0.162; Specificity, 0.950; Youden’s index, 0.112) for TTR and OS (Figure 1B) respectively, which was higher than other clinical factors.
The Prognostic Significance of SHI for HCC Patients with Negative AFP and Early-Stage Subgroups

The prognostic value of SHI for conventional low-risk or AFP ≤ 400 ng/mL subgroups was further explored. Our results showed that low SHI level was significantly associated with TTR and OS for the variables as follows: AFP ≤ 400 ng/mL for TTR (p < 0.001, Figure 2A), BCLC stages 0+A for TTR (p = 0.001, Figure 2B), AFP ≤ 400 ng/mL for OS (p < 0.001, Figure 2C), BCLC 0+A for OS (p = 0.022, Figure 2D) in the training cohort.

In the validation cohort, the prognostic value of SHI for TTR and OS in HBV-HCC patients was maintained in the AFP-negative group (p = 0.014 and p = 0.020, respectively, Figure 2) and the BCLC 0+A group (p = 0.018 and p = 0.009, respectively, Figure 2).
Correlation between SHI and SII and Its Prognostic Significance for HCC Patients with Detectable SII

The correlation between perioperative SHI score and perioperative SII score was further explored. The result showed there is a significant negative correlation between SHI and SII ($r = -0.274; p < 0.001$; Figure 3A). The SII scores were significantly higher in HBV-HCC patients with low SHI level compared with those with high SHI level (492.31 ± 88.10 vs. 327.30 ± 16.73; $p = 0.004$; Figure 3B).

In light of the close relationship between SHI and SII, we studied the prognostic significance of SHI in HBV-HCC patients with SII. HBV-HCC patients with SHI ≤ 2.84 had higher recurrence rates (61.11 vs. 29.66%; $p < 0.05$) and a shorter TTR (median, 10.9 months vs. not reached; $p = 0.011$) compared with HBV-HCC patients with SHI > 2.84 (Figure 3C). Furthermore, we also found that overall survival time was significantly lower in HBV-HCC patients with SHI ≤ 2.84 than those with SHI > 2.84 ($p = 0.008$, Figure 3D).

DISCUSSION

The blood lipid level, including triglycerides, TC, HDL, low density lipoprotein, and very low density lipoprotein, were reported to have negative correlation with the severity of liver damage in patients with HBV- or HCV-related chronic liver disease. Moreover, low TC level was reported to be in close association with severe liver fibrosis in these patients. It is implied that liver functional reserve became poorer with the decrease of TC (Vere et al., 2012; Wang et al., 2014). Several studies have shown low serum TC level and low serum HDL level were associated with worse disease-free survival and overall survival in HCC patients undergoing surgical hepatectomy, breast cancer patients, colorectal cancer patients receiving adjuvant chemotherapy, and non-small-cell lung patients with EGFR mutations (Lee et al., 2016; Li et al., 2016; Wang et al., 2016; Zhang et al., 2017). However, these studies focused on the prognostic significance of single index of TC or HDL in post-surgery patients with cancers. Combined with TC and HDL in the prognosis of HCC patient has been not reported.

In the present study, a hepatic-damage–based prognostic score was constructed based on TC and HDL levels, and was an independent factor for predicting recurrence rates and survival time of HCC patients after surgery in the training cohort. Furthermore, we collected another independent cohort of HCC patients to validate the clinical value of SHI levels, and found that the clinicopathologic characteristics of two cohorts were similar, illustrating the reliability and universality of our finding results. Meanwhile, the measurement of SHI is based on standard laboratory measurements of TC and HDL level, which are routinely performed in the clinical setting. Thus, it is a potential of SHI to be used as a marker for tumor recurrence and treatment responsiveness surveillance, which might provide a powerful test enabling accurate and early decision making to tailor the most effective therapy according to characteristics of individual tumors.
In clinical practice, it is difficult to predict tumor relapse in HCC patients with low recurrence risk. Our study demonstrated that preoperative SHI scores retain their prognostic significance in HCC patients with low recurrence risk whom conventional clinical characteristics offer limited information on predicting tumor recurrence and survival. So far, AFP has been the most extensively useful biomarker for diagnosis and treatment evolution of HCC patients (Sato et al., 1993; Johnson, 2001; Poté et al., 2015). However, it is challenging to monitor tumor recurrence and metastasis in 30–40% of low AFP levels patients with HCC (Johnson, 2001; Forner et al., 2012). Here, we have also shown that detection of the preoperative SHI level is a convenient and good tool for predicting recurrence in low AFP levels patients with HCC. The prognostic predictive value of SHI level in low recurrence risk subgroups would be that clinicians could easily identify HCC patients at high risk of tumor recurrence and metastasis, and provide targeted rational adjuvant therapy after surgery. To date, detection of SHI level has been served as a routine clinical liver function test with commercially available kits. Determination of SHI can be standardized easily to provide accuracy and reproducibility, strengthening its practical significance for determining the most effective therapy for each HCC patient at an early stage.

Recent evidence suggests that chronic immuno-inflammatory cells involve in tumorigenesis and tumor progression (Baecklund et al., 2006; Smedby et al., 2006; Lim et al., 2007). Reducing serum HDL concentration leads to chronic inflammation because of its anti-inflammatory properties. Thus, low HDL level may predict the changes of systemic inflammation and the risk of inflammation-induced tumor. Furthermore, high HDL may protect against tumor, which modulates inflammatory responses with suppressing chemotactic activity of lymphocytes and monocytes and inhibiting cytokine-induced expression of endothelial cell adhesion molecules, and protecting the integrity of lymphocytes from oxidative damage (Cockerill et al., 2001; Nofer et al., 2002; Tietge et al., 2003; Papageorgiou et al., 2016). All of those might suggest SHI affect tumor progression through modulating inflammatory responses. When analyzing only the patients with detectable SII, patients with low SHI level had a higher recurrence rate and a shorter TTR than patients with high SHI level. This suggests that SHI is unable to influence tumor cells without assistance from immune and inflammatory cells. In addition, we also found that decreased SHI was associated with vascular invasion, indicating a more aggressive phenotype. Release of tumor cells into circulation is a multiple-step procedure, which includes a great number of ingredients, and SHI acts as one of the major molecules in this procedure (Hu et al., 2014). Hence, based on our data, we believe that SHI is a significant negative regulator of SII (p < 0.001), though the correlation was relatively weak (r = -0.274). Taken together, these findings indicated that the SHI might increase the SII level by preventing tumor formation, affecting tumor cell survival in the circulation, leading to higher recurrence rates and poor outcomes in HCC patients with low serum SHI levels. Thus, improving the SHI level in HCC patients might be a promising therapeutic strategy to limit tumor recurrence and metastasis in HCC patients after surgery.

Our data shows that SHI can independently predict TTR and OS for HCC patients with resection. Furthermore, continuous monitoring of SHI in peripheral blood of HCC patients might provide available information for managing and facilitating treatment of HCC patients. The role of SHI in increasing SII scores can probably serve as the reason of high recurrence rate and poor prognosis of HCC patients with low SHI level. The cheap and easy detection of SHI level makes SHI serve as a convenient biomarker for predicting prognosis value of HCC individual in future clinical practice. Moreover, improving SHI level in peripheral blood of HCC patients might be a promising therapeutic strategy to reduce the possibility of recurrence and metastasis of HCC patients with resection. However, our study still exist several limitation. In the study, some recognized factors, such as tumor number, tumor size, and tumor differentiation are not independent risk factors for TTR and OS for HCC patients. It might be the reason of short follow-up time and small size of the cohort relatively. Moreover, it should also be noted that there is a hepatitis B virus-positive background in most HCC patients in China. Therefore, a large cohort, multicenter, long-term study including HCC patients from different background and country is needed to validate the prognostic value of SHI, and this is currently conducted in our center. Furthermore, a comprehensive study of the mechanisms of between SHI and HCC cells also needs to be explored.

AUTHOR CONTRIBUTIONS

XG and FW conceived and designed the experiments. XG and SZ performed the research, conducted the data analyses, and wrote the manuscript. HC, YW, and CY contributed to the clinical data collection. FW revised the manuscript and coordinated the research team. All authors have read and approved the final manuscript.

ACKNOWLEDGMENTS

The authors thank the participating patients for the source of clinical blood samples. This work was supported by Applied Basic Research Program of Science and Technology Bureau Foundation of Wuhan (No. 2016060101010054) and Science and Technology Innovation Fostering Foundation of Zhongnan Hospital of Wuhan University (cxpy20160025). This work was also funded by “351 talent project (Luojia Young Scholars)” of Wuhan University and National Natural Science Foundation of China (grant No. 81672114).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fphys.2017.00480/full#supplementary-material

**Supplementary Table 1** | The area under curve for TTR and OS in the training and validation cohort. TTR, Time to recurrence; OS, Overall survival; AUC, area under curve; CI, confidence interval; AFP, a-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; SHI, systemic hepatic-damage index.

**Supplementary Figure 1** | The optimal cutoff value of SHI was selected by X-tile 3.6.1 software. SHI, systemic hepatic-damage index.
REFERENCES

Baecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., et al. (2006). Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54, 692–701. doi: 10.1002/art.21675

Bruix, J., and Sherman, M. (2011). Management of hepatocellular carcinoma: an update. Hepatology 53, 1020–1022. doi: 10.1002/hep.24199

Camp, R. L., Dollé-Filhart, M., and Rimm, D. L. (2004). X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 10, 7252–7259. doi: 10.1158/1078-0432.CCR-04-0713

Casadei, G. A., Scarpi, E., Faloppi, L., Scartozzi, M., Silvestris, N., Santini, D., et al. (2016). Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget 7, 67142–67149. doi: 10.18632/oncotarget.11565

Chaffer, C. L., and Weinberg, R. A. (2011). A perspective on cancer cell metastasis. Science 331, 1559–1564. doi: 10.1126/science.1205543

Cockerill, G. W., Huehns, T. Y., Weerasinghe, A., Stocker, C., Lerch, P. G., Miller, N. E., et al. (2001). Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 103, 108–112. doi: 10.1161/01.CIR.103.1.108

Forner, A., Llovet, J. M., and Bruix, J. (2012). Hepatocellular carcinoma. Lancet 379, 1245–1255. doi: 10.1016/S0140-6736(11)61347-0

Forner, A., and Raoul, J. L. (2011). Non-invasive diagnostic criteria for hepatocellular carcinoma: the value of contrast washout at imaging and the death of alpha-fetoprotein. Liver Int. 31, 1419–1421. doi: 10.1111/j.1478-3231.2011.02605.x

Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646–664. doi: 10.1016/j.cell.2011.02.013

Hu, B., Yang, X. R., Xu, Y. F., Sun, C., Guo, W., et al. (2014). Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin. Cancer Res. 20, 6212–6222. doi: 10.1158/1078-0432.CCR-14-0442

Irshad, M., Dube, R., and Joshi, Y. K. (2007). Impact of viral hepatitis on apo- and lipoprotein status in blood. Med. Princ. Pract. 16, 310–314. doi: 10.1159/000101215

Ji, J., Shi, J., Budhu, A., Yu, Z., Forgues, M., Roessler, S., et al. (2009). MicroRNA expression, survival, and response to interferon in liver cancer. J. Exp. Med. 361, 1437–1447. doi: 10.1086/NEJMoa0901522

Johnson, P. J. (2001). The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin. Liver Dis. 5, 145–159. doi: 10.1016/S1089-3261(05)61185-8

Lee, Y. L., Li, W. C., Tsai, T. H., Chiang, H. Y., and Tsai, C. T. (2016). Body mass index and cholesterol level predict surgical outcome in patients with hepatocellular carcinoma in Taiwan—a cohort study. Oncotarget 7, 22948–22959. doi: 10.18632/oncotarget.10145

Li, X., Tang, H., Wang, J., Xu, X., Liu, Y., Zhang, Y., et al. (2016). The effect of preoperative serum sPLA2 overexpression and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast 32, 1–6. doi: 10.1016/j.breast.2016.01.004

Lim, U., Gayles, T., Katki, H. A., Stolzenberg-Solomon, R., Weinstein, S. J., Pietinen, P., et al. (2007). Serum high-density lipoprotein cholesterol and risk of non-Hodgkin lymphoma. Cancer Res. 67, 5569–5574. doi: 10.1158/0008-5472.CAN-07-0212

Nofer, J. R., Kehrel, B., Fobker, M., Levkau, B., Assmann, G., and von Eckardstein, A. (2002). HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161, 1–16. doi: 10.1016/S0021-9150(01)00651-7

Papageorgiou, N., Zacharia, E., Androulakis, E., Briasoulis, A., Charakida, M., and Tousoulis, D. (2016). HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation. Expert Opin. Ther. Targets 20, 907–921. doi: 10.1517/14728222.2016.1153264

Potz, N., Caucy, F., Albuquerque, M., Voitot, H., Belghiti, J., Castera, L., et al. (2015). Performance of PIIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J. Hepatol. 62, 848–854. doi: 10.1016/j.jhep.2014.11.005

Sato, Y., Nakata, K., Kato, Y., Shima, M., Ishii, N., Koji, T., et al. (1993). Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N. Engl. J. Med. 328, 1802–1806. doi: 10.1056/NEJM199306243282202

Smedby, K. E., Hjalgrim, H., Aslung, J., Chang, E. T., Gregersen, H., Porwit-MacDonald, A., et al. (2006). Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J. Natl. Cancer Inst. 98, 51–60. doi: 10.1093/jnci/dji004

Tietje, U. J., Maegaus, C., Cain, W., and Rader, D. J. (2003). Acute inflammation increases selective uptake of HDL cholesteryl esters into alveolar cells of mice overexpressing human sPLA2. Am. J. Physiol. Endocrinol. Metab. 285, E403–411. doi: 10.1152/ajpendo.00576.2002

Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108. doi: 10.3322/caac.21266

Vere, C. C., Streba, G. T., Streba, I., and Rogozanou, I. (2012). Lipid serum profile in patients with viral liver cirrhosis. Med. Princ. Pract. 21, 566–568. doi: 10.1159/000339227

Wang, G., Liu, W. Y., Zhang, B., Zhang, Z., Huang, Z., Luo, H., et al. (2014). Preoperative total cholesterol predicts postoperative outcomes after partial hepatectomy in patients with chronic hepatitis B- or C-related hepatocellular carcinoma. Surgery 55, 263–270. doi: 10.1016/j.surg.2013.08.017

Wang, Y., Wang, Z., Q., Wang, F. H., Lei, X. F., Yan, S. M., Wang, D. S., et al. (2016). Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget 7, 57290–57300. doi: 10.18632/oncotarget.10145

Witekind, C. (2006). Pitfalls in the classification of liver tumors. Am. J. Physiol. Endocrinol. Metab. 290, 140, 1645–1652. doi: 10.1159/000339206

Zhang, Y., Xu, J., Lou, Y., Hu, S., Yu, K., Li, R., et al. (2017). Pretreatment direct SHi in the HCC 2017 | Volume 8 | Article 480 140, 1645–1652. doi: 10.1159/000339206

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Gao, Zhang, Chen, Wang, Yuan and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.